Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring

References

• Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001 Sep;50(3):389–400. PubMed PMID: 11558796.
   PubMed Web of Science ®Google Scholar
• Wegner C, Esiri MM, Chance SA, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006 Sep 26;67(6):960–967. PubMed PMID: 17000961.
   PubMed Web of Science ®Google Scholar
• Vercellino M, Merola A, Piacentino C, et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol. 2007 Aug;66(8):732–739. PubMed PMID: 17882017.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):477–493. PubMed PMID: 20976767.
   PubMed Web of Science ®Google Scholar
• Klaver R, Popescu V, Voorn P, et al. Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol. 2015 May;74(5):453–458. PubMed PMID: 25853695.
   PubMed Web of Science ®Google Scholar
• Jurgens T, Jafari M, Kreutzfeldt M, et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain. 2016 Jan;139(Pt 1):39–46. PubMed PMID: 26667278.
   PubMedGoogle Scholar
• Carassiti D, Altmann DR, Petrova N, et al. Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex. Neuropathol Appl Neurobiol. 2017 Apr 18. DOI:10.1111/nan.12405. PubMed PMID: 28419506.
   PubMedGoogle Scholar
• Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain. 1997 Mar;120(Pt 3):393–399. PubMed PMID: 9126051.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278–285. PubMed PMID: 9445407.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 Nov;128(Pt 11):2705–2712. PubMed PMID: 16230320.
   PubMed Web of Science ®Google Scholar
• Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol.. 2000 Jul;157(1):267–276. PubMed PMID: 10880396.
   PubMed Web of Science ®Google Scholar
• Preziosa P, Kiljan S, Steenwijk MD, et al. Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex. Brain. 2019 Jul 1;142(7):1921–1937. PubMed PMID: 31168614.
   PubMedGoogle Scholar
• Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler. 2010 Apr;16(4):406–411. PubMed PMID: 20215480.
   PubMed Web of Science ®Google Scholar
• Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012 Nov 5;8(11):647–656. PubMed PMID: 23007702.
   PubMed Web of Science ®Google Scholar
• Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018 Nov 8;4(1):43. 10.1038/s41572-018-0041-4. PubMed PMID: 30410033.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015 Feb;14(2):183–193. PubMed PMID: 25772897.
   PubMed Web of Science ®Google Scholar
• Filippi M, Bruck W, Chard D, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2019 Feb;18(2):198–210. PubMed PMID: 30663609.
   PubMed Web of Science ®Google Scholar
• van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999 Nov;46(5):747–754. PubMed PMID: 10553992.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am. 2000 Nov;10(4):739–52,ix. PubMed PMID: 11359722.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Comi G, Filippi M. The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. Front Neurol. 2017;8:433. PubMed PMID: 28928705.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Battaglini M, Benedict RH, et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology. 2017 Jan 24;88(4):403–413. PubMed PMID: 27986875.
   PubMed Web of Science ®Google Scholar
• Filippi M, Preziosa P, Rocca MA. Microstructural MR Imaging Techniques in Multiple Sclerosis. Neuroimaging Clin N Am. 2017 May;27(2):313–333. PubMed PMID: 28391789.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging. 2007 Apr;17 Suppl 1:31S–35S. PubMed PMID: 17425732.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 10.1038/s41582-018-0058-z. PubMed PMID: 30171200. 2018 Oct;14(10):577–589.
   PubMed Web of Science ®Google Scholar
• Yuan A, Rao MV, Veeranna, et al. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):a018309. PubMed PMID: 28373358.
   PubMed Web of Science ®Google Scholar
• Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020 Feb 10;11(1):812. 10.1038/s41467-020-14612-6. PubMed PMID: 32041951.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870–881. PubMed PMID: 30967444.
   PubMed Web of Science ®Google Scholar
• Herrmann H, Aebi U. Intermediate Filaments: structure and Assembly. Cold Spring Harb Perspect Biol. 2016 Nov 1;8(11):a018242. PubMed PMID: 27803112.
   PubMed Web of Science ®Google Scholar
• Norgren N, Karlsson JE, Rosengren L, et al. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 2002 Feb;21(1):53–59. PubMed PMID: 11991817.
   PubMedGoogle Scholar
• Petzold A, Keir G, Green AJ, et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods. 2003 Jul;278(1–2):179–190. PubMed PMID: 12957406.
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Warren J, et al. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis. 2007;4(2–3):185–194. PubMed PMID: 17596713.
   PubMed Web of Science ®Google Scholar
• Petzold A, Altintas A, Andreoni L, et al. Neurofilament ELISA validation. J Immunol Methods. 2010 Jan 31;352(1–2):23–31. PubMed PMID: 19857497.
   PubMed Web of Science ®Google Scholar
• Limberg M, Disanto G, Barro C, et al. Neurofilament Light Chain Determination from Peripheral Blood Samples. Methods Mol Biol. 2016;1304:93–98. PubMed PMID: 25687302.
   PubMedGoogle Scholar
• Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016 Oct 1;54(10):1655–1661. PubMed PMID: 27071153.
   PubMed Web of Science ®Google Scholar
• Fialova L, Bartos A, Svarcova J, et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol. 2013 Sep 15;262(1–2):113–120. PubMed PMID: 23870535.
   PubMed Web of Science ®Google Scholar
• Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun;81(6):857–870. PubMed PMID: 28512753.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Disanto G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016 Oct;22(12):1550–1559. PubMed PMID: 26754800.
   PubMed Web of Science ®Google Scholar
• Novakova L, Zetterberg H, Sundstrom P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017 Nov 28;89(22):2230–2237. PubMed PMID: 29079686.
   PubMed Web of Science ®Google Scholar
• Piehl F, Kockum I, Khademi M, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2018 Jul;24(8):1046–1054. PubMed PMID: 28627962.
   PubMed Web of Science ®Google Scholar
• Hakansson I, Tisell A, Cassel P, et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation. 2018 Jul 18;15(1):209. 10.1186/s12974-018-1249-7. PubMed PMID: 30021640.
   PubMedGoogle Scholar
• Dalla Costa G, Martinelli V, Sangalli F, et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019 Feb 12;92(7):e733–e741. PubMed PMID: 30635483.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Plavina T, Barro C, et al. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler. 2019 Nov 4:1352458519885613. DOI:10.1177/1352458519885613. PubMed PMID: 31680621.
   Google Scholar
• Thebault S, Tessier DR, Lee H, et al. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol Neuroimmunol Neuroinflamm. 2019 Sep;6(5):e598. PubMed PMID: 31516913.
   PubMed Web of Science ®Google Scholar
• Wong YYM, Bruijstens AL, Barro C, et al. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology. 2019 Sep 3;93(10):e968–e974. PubMed PMID: 31383792.
   PubMed Web of Science ®Google Scholar
• de Flon P, Laurell K, Sundstrom P, et al. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol Scand. 2019 May;139(5):462–468. PubMed PMID: 30740668.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Blennow K, Hagberg L, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017 Aug;17(8):761–770. PubMed PMID: 28598205.
   PubMed Web of Science ®Google Scholar
• Tiedt S, Duering M, Barro C, et al. Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology. 2018 Oct 2;91(14):e1338–e1347. PubMed PMID: 30217937.
   PubMed Web of Science ®Google Scholar
• de Flon P, Gunnarsson M, Laurell K, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016 Jul 12;87(2):141–147. PubMed PMID: 27316241.
   PubMed Web of Science ®Google Scholar
• Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002 Jan;122(1–2):132–139. PubMed PMID: 11777552.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 Apr 14;72(15):1322–1329. PubMed PMID: 19365053.
   PubMed Web of Science ®Google Scholar
• Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 Jan;69(1):83–89. PubMed PMID: 21280078.
   PubMed Web of Science ®Google Scholar
• Avsar T, Korkmaz D, Tutuncu M, et al. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler. 2012 Aug;18(8):1081–1091. PubMed PMID: 22252467.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013 Oct;19(12):1597–1603. PubMed PMID: 23529999.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Bornsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2013 Jun;19(7):877–884. PubMed PMID: 23178691.
   PubMed Web of Science ®Google Scholar
• Modvig S, Degn M, Horwitz H, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One. 2013;8(10):e77163. PubMed PMID: 24116216.
   PubMed Web of Science ®Google Scholar
• Madeddu R, Farace C, Tolu P, et al. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol Sci. 2013 Feb;34(2):181–186. PubMed PMID: 22362332.
   PubMed Web of Science ®Google Scholar
• Khalil M, Enzinger C, Langkammer C, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2013 Apr;19(4):436–442. PubMed PMID: 22917689.
   PubMed Web of Science ®Google Scholar
• Stilund M, Gjelstrup MC, Petersen T, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015;10(4):e0119681. PubMed PMID: 25860354.
   PubMed Web of Science ®Google Scholar
• Gil-Perotin S, Castillo-Villalba J, Cubas-Nunez L, et al. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front Neurol. 2019;10:1008. PubMed PMID: 31608004.
   PubMed Web of Science ®Google Scholar
• Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126–129. PubMed PMID: 25716934.
   PubMed Web of Science ®Google Scholar
• Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018 Aug 1;141(8):2382–2391. PubMed PMID: 29860296.
   PubMedGoogle Scholar
• Jakimovski D, Kuhle J, Ramanathan M, et al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol. 2019 Sep;6(9):1757–1770. PubMed PMID: 31437387.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Zivadinov R, Ramanthan M, et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Mult Scler. 2019 Oct 15:1352458519881428. DOI:10.1177/1352458519881428. PubMed PMID: 31610732.
   Web of Science ®Google Scholar
• Bjornevik K, Munger KL, Cortese M, et al. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 2019 Sep 13. PubMed PMID: 31515562. DOI:10.1001/jamaneurol.2019.3238
   PubMed Web of Science ®Google Scholar
• Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 Dec 23;61(12):1720–1725. PubMed PMID: 14694036.
   PubMed Web of Science ®Google Scholar
• Aeinehband S, Lindblom RP, Al Nimer F, et al. Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One. 2015;10(4):e0122048. PubMed PMID: 25835709.
   PubMed Web of Science ®Google Scholar
• Villar LM, Picon C, Costa-Frossard L, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. 2015 Aug;22(8):1169–1175. PubMed PMID: 25324032.
   PubMed Web of Science ®Google Scholar
• Novakova L, Axelsson M, Khademi M, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017 Apr;141(2):296–304. PubMed PMID: 27787906.
   PubMed Web of Science ®Google Scholar
• Martinez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015 Apr;21(5):550–561. PubMed PMID: 25732842.
   PubMed Web of Science ®Google Scholar
• Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014 Jan;20(1):43–50. PubMed PMID: 23702432.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Eusebi P, Mancini A, et al. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Mult Scler Relat Disord. 2019 Oct;35:228–232. PubMed PMID: 31404762.
   PubMed Web of Science ®Google Scholar
• Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402–404. PubMed PMID: 9527161.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019 Mar 5;92(10):e1007–e1015. PubMed PMID: 30737333.
   PubMed Web of Science ®Google Scholar
• Filippi M, Preziosa P, Rocca MA. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol. 2014 Jun;27(3):290–299. PubMed PMID: 24792339.
   PubMed Web of Science ®Google Scholar
• Burman J, Zetterberg H, Fransson M, et al. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand. 2014 Aug;130(2):81–89. PubMed PMID: 24571714.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015 Apr 21;84(16):1639–1643. PubMed PMID: 25809304.
   PubMed Web of Science ®Google Scholar
• Arrambide G, Espejo C, Eixarch H, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13;87(11):1076–1084. PubMed PMID: 27521440.
   PubMed Web of Science ®Google Scholar
• Novakova L, Axelsson M, Khademi M, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. 2017 Jan;23(1):62–71. PubMed PMID: 27003946.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Nourbakhsh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017 Feb 28;88(9):826–831. PubMed PMID: 28148632.
   PubMed Web of Science ®Google Scholar
• Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec;5(12):1478–1491. PubMed PMID: 30564615.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Sellebjerg F, Hartung H-P, et al. Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study. https://onlinelibraryectrims-congresseu/ectrims/2018/ectrims-2018/228118/rajkapoornatalizumabreducedserumlevelsofneurofilamentlightchaininhtml. 2018.
   Google Scholar
• Canto E, Barro C, Zhao C, et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol. 2019;76(11):1359-1366. PubMed PMID: 31403661.
   PubMed Web of Science ®Google Scholar
• Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019 Apr;25(5):678–686. PubMed PMID: 29542376.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Royen L, Soelberg Sorensen P, et al. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler. 2019 Oct;25(11):1444–1451. PubMed PMID: 30113249.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010 Mar;16(3):287–292. PubMed PMID: 20086018.
   PubMed Web of Science ®Google Scholar
• Hakansson I, Tisell A, Cassel P, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017 May;24(5):703–712. PubMed PMID: 28261960.
   PubMed Web of Science ®Google Scholar
• Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015 Dec;21(14):1761–1770. PubMed PMID: 25698172.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Salvadori N, Lisetti V, et al. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. J Neurol. 2019 Sep;266(9):2157–2163. 10.1007/s00415-019-09398-7. PubMed PMID: 31129709.
   PubMed Web of Science ®Google Scholar
• Tortorella C, Direnzo V, Ruggieri M, et al. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2018 Jul;24(8):1039–1045. PubMed PMID: 28537100.
   PubMed Web of Science ®Google Scholar
• Trentini A, Comabella M, Tintore M, et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol. 2014 Dec;261(12):2338–2343. PubMed PMID: 25228004.
   PubMed Web of Science ®Google Scholar
• Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017 Jun;16(6):445–451. PubMed PMID: 28434855.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Giorgio A, Tintore M, et al. Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Mult Scler. 2018 Feb;24(2):214–221. PubMed PMID: 29451440.
   PubMed Web of Science ®Google Scholar
• Matute-Blanch C, Villar LM, Alvarez-Cermeno JC, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018 Apr 1;141(4):1085–1093. PubMed PMID: 29452342.
   PubMedGoogle Scholar
• Kuhle J, Malmestrom C, Axelsson M, et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand. 2013 Dec;128(6):e33–6. PubMed PMID: 23763388.
   PubMed Web of Science ®Google Scholar
• Dalla Costa G, Martinelli V, Moiola L, et al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol. 2019 Apr;85(4):606–610. PubMed PMID: 30761586.
   PubMed Web of Science ®Google Scholar
• Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004 Nov 9;63(9):1586–1590. PubMed PMID: 15534240.
   PubMed Web of Science ®Google Scholar
• Bhan A, Jacobsen C, Myhr KM, et al. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. 2018 Sep;24(10):1301–1307. PubMed PMID: 30066611.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Kropshofer H, Haering DA, et al. Neurofilament light levels in the blood of patients with secondary progressive MS are higher than in primary progressive MS and may predict brain atrophy in both MS subtypes. https://onlinelibraryectrims-congresseu/ectrims/2018/ectrims-2018/232039/ludwigkapposneurofilamentlightlevelsinthebloodofpatientswithhtml?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D22425. 2018.
   Google Scholar
• Mellergard J, Tisell A, Blystad I, et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. 2017 Jan;24(1):112–121. PubMed PMID: 27699930.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014 Apr 29;82(17):1499–1507. PubMed PMID: 24682973.
   PubMed Web of Science ®Google Scholar
• Loonstra FC, Verberk IMW, Wijburg MT, et al. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Ann Neurol. 2019 Aug;86(2):322–324. PubMed PMID: 31192473.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Daizadeh N, Barro C, et al. Alemtuzumab reduces serum neurofilament light chain levels in relapsing-remitting multiple sclerosis patients from the CARE-MS I study. https://onlinelibraryectrims-congresseu/ectrims/2018/ectrims-2018/228125/jenskuhlealemtuzumabreducesserumneurofilamentlightchainlevelsinhtml. 2018.
   Google Scholar
• Akgun K, Kretschmann N, Haase R, et al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol Neuroinflamm. 2019 May;6(3):e555. PubMed PMID: 31119188.
   PubMed Web of Science ®Google Scholar
• Delcoigne B, Manouchehrinia A, Barro C, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94(11):e1201–e1212. PubMed PMID: 32047070.
   PubMed Web of Science ®Google Scholar
• Ratzer R, Iversen P, Bornsen L, et al. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Mult Scler. 2016 Jun;22(7):926–934. PubMed PMID: 26432857.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Haering DA, Kropshofer H, et al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann Clin Transl Neurol. 2019 Jun;6(6):1081–1089. PubMed PMID: 31211172.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Hrusovsky K, et al. International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients. https://onlinelibraryectrims-congresseu/ectrims/2018/ectrims-2018/228383/jenskuhleinternationalmulti-siteanalyticalvalidationofthesimoahtml. 2018.
   Google Scholar
• Bonnan M, Marasescu R, Demasles S, et al. No evidence of disease activity (NEDA) in MS should include CSF biology - Towards a ‘Disease-Free Status Score’. Mult Scler Relat Disord. 2017 Jan;11:51–55. PubMed PMID: 28104257.
   PubMed Web of Science ®Google Scholar
• Martin SJ, McGlasson S, Hunt D, et al. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1059–1067. PubMed PMID: 31123141.
   PubMed Web of Science ®Google Scholar